The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania

Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines

(2016) Stephen M. Stahl   CNS SPECTRUMS

Iloperidone, asenapine and lurasidone: a primer on their current status

(2012) Frank I Tarazi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

(2011) Armin Szegedi et al.   BMC Psychiatry

The role of serotonin receptors in the action of atypical antipsychotic drugs

(2011) HY Meltzer et al.   CURRENT OPINION IN PHARMACOLOGY

Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder

(2011) Armin Szegedi et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration

(2011) John D. Elsworth et al.   NEUROPHARMACOLOGY

Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy

(2011) Ouissame Mnie-Filali et al.   NEUROPSYCHOPHARMACOLOGY

Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat

(2010) Samantha L. McLean et al.   BEHAVIOURAL BRAIN RESEARCH

Therapeutic Options for Treatment-Resistant Depression

(2010) Richard C. Shelton et al.   CNS DRUGS

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats

(2010) Jorn Arnt et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia

(2010) John M. Kane et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Attenuation of chronic mild stress-induced ‘anhedonia’ by asenapine is not associated with a ‘hedonic’ profile in intracranial self-stimulation

(2010) Hugh M Marston et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism

(2010) Joanna C. Neill et al.   PHARMACOLOGY & THERAPEUTICS

Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism

(2010) Shikha Snigdha et al.   PSYCHOPHARMACOLOGY

The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?

(2010) R. W. Buchanan et al.   SCHIZOPHRENIA BULLETIN

INVESTIGATION INTO COGNITIVE FUNCTION IN FIRST EPISODE PSYCHOSIS PATIENTS

(2010) Majid M. Saleem et al.   SCHIZOPHRENIA RESEARCH

The Serotonin-1A Receptor in Anxiety Disorders

(2009) Elena Akimova et al.   BIOLOGICAL PSYCHIATRY

D1-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia

(2009) Samantha L. McLean et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors

(2009) Yong Kee Choi et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

(2009) Herbert Y. Meltzer et al.   JOURNAL OF CLINICAL PSYCHIATRY

5-HT1A receptor function in major depressive disorder

(2009) Jonathan Savitz et al.   PROGRESS IN NEUROBIOLOGY

Asenapine effects in animal models of psychosis and cognitive function

(2009) Hugh M. Marston et al.   PSYCHOPHARMACOLOGY

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms

(2009) Nagi Idris et al.   PSYCHOPHARMACOLOGY

Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

(2009) Frank I. Tarazi et al.   SYNAPSE

Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors

(2008) Shikha Snigdha et al.   BEHAVIOURAL BRAIN RESEARCH

Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology

(2008) Rodrigo D. Paz et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α2-adrenergic and D2 receptors in the rat brain

(2008) Ramez Ghanbari et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

(2008) Elizabeth Scarr et al.   JOURNAL OF NEUROCHEMISTRY

Asenapine induces differential regional effects on serotonin receptor subtypes

(2008) FI Tarazi et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

(2008) M. Shahid et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Asenapine Increases Dopamine, Norepinephrine and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus

(2008) Mei Huang et al.   NEUROPSYCHOPHARMACOLOGY

Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions

(2008) David S. Tait et al.   PSYCHOPHARMACOLOGY

Differential regional and dose-related effects of asenapine on dopamine receptor subtypes

(2008) Frank I. Tarazi et al.   PSYCHOPHARMACOLOGY